Immunosuppressive medication is not associated with surgical site infection after surgery for intractable ulcerative

Keiichi Uchida1,2, Yoshikazu Ohtsuka2,3, Atsushi Yoden2,4

  • 1Department of Gastrointestinal and Pediatric Surgery, Mie University Graduate School of Medicine, Mie, Japan.

Insights

In pediatric ulcerative colitis (UC) surgery, three-stage procedures and female sex independently predict postoperative surgical site infections (SSIs). Preoperative immunosuppressive drugs did not significantly impact SSI rates in this Japanese study.

Area of Science:

  • Gastroenterology
  • Pediatric Surgery
  • Infectious Diseases

Background:

  • Pediatric ulcerative colitis (UC) can become medically intractable, necessitating complex surgical interventions.
  • Surgical management of pediatric UC is associated with challenging procedures and a high risk of infectious complications.
  • Understanding risk factors for postoperative surgical site infections (SSIs) is crucial for improving outcomes in pediatric UC patients.

Purpose of the Study:

  • To survey surgical procedures and infectious complications in pediatric patients with UC in Japan.
  • To assess the relationship between preoperatively administered immunosuppressive drugs and postoperative SSIs.
  • To identify independent predictors of postoperative SSIs in pediatric UC patients undergoing surgery.

Main Methods:

  • A nationwide survey of pediatric UC patients treated between 2000 and 2012 was conducted.
  • Secondary questionnaires focused on postoperative SSIs, patient characteristics, disease severity, medications, and operative procedures.
  • Multiple logistic regression analysis was used to assess associations between variables and SSI development.

Main Results:

  • Data from 136 pediatric UC patients were analyzed; 26% (36/136) developed SSIs.
  • Three-stage surgery (compared to one or two stages) and female sex were statistically significant predictors of SSI.
  • Preoperative immunosuppressive medications were not significantly associated with the incidence of postoperative SSIs.

Conclusions:

  • Three-stage surgical procedures and female sex are independent predictors of postoperative SSIs in pediatric UC patients.
  • Preoperative immunosuppressive medication use does not appear to influence the incidence of SSIs in this population.
  • These findings highlight the importance of considering surgical approach and patient sex in managing SSI risk.

Related Concept Videos

Inflammatory Bowel Disease V: Surgical Management01:21

Inflammatory Bowel Disease V: Surgical Management

Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
780
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
577
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
608
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
577
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
862
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents01:24

Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents

In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
1.8K